Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives

American Journal of Epidemiology

Volumn 152, Issue 3, 2000, Pages 233-241

  Ness, Roberta B ^a   Grisso, Jeane Ann ^b   Klapper, Jennifer ^b   Schlesselman, James J ^c   Silberzweig, Stacey ^b   Vergona, Ron ^a   Morgan, Mark ^b   Wheeler, James E ^b  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Contraceptives, oral; Estrogens; Ovarian neoplasms; Progestational hormones

Indexed keywords

ESTROGEN; GESTAGEN; LOW DOSE ORAL CONTRACEPTIVE; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY CANCER; RISK FACTOR; UNITED STATES;

ADULT; AGED; BODY MASS INDEX; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; FEMALE; HUMANS; MID-ATLANTIC REGION; MIDDLE AGED; OVARIAN NEOPLASMS; PARITY; PROGESTINS; RISK FACTORS;

EID: 0034255545     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/152.3.233     Document Type: Article

References (30)

1. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies II. Invasive epithelial ovarian cancers in White women
2. Oral contraceptives and neoplasia of the ovary
3. On the epidemiology of oral contraceptives and disease
4. The epidemiology of ovarian cancer
5. Oral contraceptives in the United States: Trends in content and potency
6. Comparison of the effects of contraceptive steroid formulations containing two doses of estrogen on pituitary function
7. Pituitary and ovarian responsiveness to a graded gonadotropin releasing factor stimulation test in women using a low-estrogen or a regular type of oral contraceptive
8. +
9. Ovarian cancer
10. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis
11. High-dose and low-dose combined oral contraceptives: Protection against epithelial ovarian cancer and the length of the protective effect
12. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral-contraceptive use
13. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer
14. The estrogenic potency of ethinylestradiol and mestranol - A comparative study
15. Pharmacokinetics of mestranol in man in relation to its estrogenic activity
16. Oral contraceptives in the United States: Trends in content and potency
17. Progestational potency of oral contraceptives
18. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study
19. Differences in risk factors for epithelial ovarian cancer by histologic type: Results of a case-control study
20. A case-control study of epithelial ovarian cancer
21. A prospective study of reproductive factors and risk of epithelial ovarian cancer
22. Oral contraceptives and the risk of hereditary ovarian cancer
23. Modern oral contraceptives and cardiovascular disease
24. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
25. Recall accuracy for prescription medications: Self-report compared with database information
26. The ability of women to recall their oral contraceptive histories
27. The agreement between questionnaire data and medical records: The evidence for accuracy of recall